Novo Nordisk Wegovy Price Cuts and Subscriptions
Novo Nordisk Wegovy price cuts broaden access via U.S. multi-month subscriptions and India dose reductions while raising pressure on Eli Lilly.
KEY TAKEAWAYS
- Novo Nordisk launched U.S. multi-month Wegovy subscriptions via NovoCare.
- Subscriptions priced at $349/month versus a $1,349 list give cash-pay patients predictable costs.
- India starting-dose cuts of 48% for Wegovy and 36% for Ozempic lower entry prices versus generics.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Novo Nordisk A/S (NVO) introduced Wegovy price cuts on March 31, 2026, alongside a U.S. rollout of discounted multi-month subscriptions and dose-price reductions in India. These moves aim to broaden access and intensify competition with Eli Lilly in the obesity treatment market.
U.S. Subscriptions and NovoCare Pricing
Novo Nordisk launched discounted multi-month Wegovy subscription plans for U.S. self-pay patients through its NovoCare channel. The plans offer three-, six-, and 12-month options covering the Wegovy injection and the two highest doses of the brand’s recently launched pill. Wegovy is an FDA-approved glucagon-like peptide-1 (GLP-1) therapy for obesity.
NovoCare pricing sets a new baseline for self-pay customers: the standard list price is $1,349 per month, while the subscription costs $349 monthly. An introductory rate of $199 per month applies to the lowest Wegovy doses for the first two fills. Subscription tiers run up to nearly 30% below the standard list price, targeting cash-paying patients seeking lower, more predictable out-of-pocket costs.
Additionally, an expanded collaboration with Weight Watchers Med+ offers eligible members up to $1,200 annually in savings on Wegovy through the subscription channel.
India Price Cuts and Market Context
Effective April 1, 2026, India’s starting doses for Ozempic and Wegovy 0.25 mg will cost Rs 1,415 per week. This represents a 48% reduction for Wegovy’s starting dose from Rs 2,712 and a 36% cut for Ozempic’s 0.25 mg dose, translating to a daily cost of Rs 202 including taxes. The price cuts reflect a strategy to lower entry-level prices in a market sensitive to generics and price competition.
Higher Ozempic doses in India were also repriced: the 0.5 mg dose is Rs 2,025 per week, and the 1 mg dose is Rs 2,275 per week.
Together, the U.S. subscription program, NovoCare pricing, Weight Watchers collaboration, and India dose-price reductions aim to expand lower-cost access for cash-paying patients. These initiatives are positioned to sharpen price competition globally, particularly against Eli Lilly and local generics.
